Acquisition combines 4E's innovative MNK inhibitor with Lilly's broad neuroscience capabilities and portfolio

此次收购将4E公司创新的MNK抑制剂与礼来公司在神经科学领域的广泛能力及产品组合相结合

AUSTIN, Texas

德克萨斯州，奥斯汀

,

，

June 16, 2026

2026年6月16日

/PRNewswire/ -- 4E Therapeutics, Inc. ('4E'), an Austin-based neuroscience company developing next-generation treatments for chronic pain, today announced that it has been acquired by Eli Lilly and Company ('Lilly').

/美通社/ -- 总部位于奥斯汀的神经科学公司4E Therapeutics, Inc.（“4E”）致力于开发慢性疼痛的下一代疗法，今日宣布已被礼来公司（“Lilly”）收购。

4E is developing a pipeline of orally available MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons. The compounds are intended to deliver meaningful pain relief while avoiding the central nervous system effects associated with many existing therapeutics.

4E公司正在开发一系列口服可用的MNK抑制剂，旨在通过靶向外周感觉神经元中的MNK-eIF4E信号通路来治疗慢性疼痛。这些化合物意在提供显著的疼痛缓解，同时避免与许多现有疗法相关的中枢神经系统副作用。

The company's lead compound, 4ET1103, is the first MNK inhibitor developed to treat pain to advance to human clinical trials, where it demonstrated a favorable safety profile in a Phase 1 study..

该公司的领先化合物4ET1103是首个进入人体临床试验的用于疼痛治疗的MNK抑制剂，在I期研究中展现出良好的安全性。

'We founded 4E Therapeutics with a simple but ambitious goal: to develop innovative, non-opioid therapies that address the underlying neurological mechanisms that cause pain,' said Joe Price, Co-Founder, President and Chairman of 4E Therapeutics. 'Lilly's clinical development, translational, and global commercial capacity – and its deep commitment to tackling the challenges of chronic pain for patients – make it the right home for realizing the full potential of this work for patients.'.

“我们创立4E Therapeutics时，怀着一个简单而雄心勃勃的目标：开发创新的非阿片类疗法，以解决导致疼痛的根本神经机制，”4E Therapeutics的联合创始人、总裁兼董事长Joe Price表示。“礼来公司在临床开发、转化研究以及全球商业化方面的能力，加上其致力于应对患者慢性疼痛挑战的深厚承诺，使其成为实现这一工作对患者全部潜力的理想归宿。”

'Seeing this science – years of research into the molecular events that cause pain to become chronic – advance from basic research to clinical development and now to Lilly's pipeline, provides excitement for the opportunity to accelerate new therapies to patients living with chronic pain,' said Theodore Price, Ph.D., Co-Founder of 4E Therapeutics and Director of the Center for Advanced Pain Studies at The University of Texas at Dallas..

“目睹这一科学领域——即针对导致疼痛慢性化的分子事件所开展的多年研究——从基础研究推进至临床开发，并最终纳入礼来公司的研发管线，令我们倍感振奋，因为这为加速向慢性疼痛患者提供新疗法带来了契机。”德克萨斯大学达拉斯分校高级疼痛研究中心主任、4E Therapeutics 联合创始人西奥多·普莱斯博士表示。

Terms of the transaction were not disclosed.

交易条款未予披露。

4E's exclusive financial advisor was Aquilo Partners LP and Wilson Sonsini Goodrich & Rosati LLP provided legal counsel to 4E.

4E的独家财务顾问为Aquilo Partners LP，Wilson Sonsini Goodrich & Rosati LLP为4E提供了法律顾问服务。

About 4E Therapeutics

关于4E Therapeutics

4E Therapeutics is a neuroscience company focused on developing innovative, non-addictive therapies for chronic pain. The company was founded based on pioneering discoveries in the biology of pain and is advancing a portfolio of programs targeting neuropathic pain, migraine, acute pain, and related conditions through a novel mechanism designed to interrupt pain signaling at its source.

4E Therapeutics 是一家神经科学公司，专注于开发用于慢性疼痛治疗的创新且非成瘾性疗法。该公司基于在疼痛生物学领域的开创性发现而成立，并通过一种旨在从源头阻断疼痛信号传导的新颖机制，推进针对神经病理性疼痛、偏头痛、急性疼痛及相关病症的项目组合。

4E's medicinal chemistry and drug development has been led by James Sahn, Vice President of Drug Development. T. Craig Benson, a serial biotechnology and life sciences entrepreneur, has led 4E from its founding as CEO..

4E的药物化学与药物研发工作由药物开发副总裁詹姆斯·萨恩（James Sahn）领导。连续生物技术及生命科学创业者T.克雷格·本森（T. Craig Benson）自公司创立以来一直担任首席执行官，领导4E的发展。

SOURCE 4E Therapeutics

来源：4E Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示